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Background: Depot formulations of antipsychotics provide a potential solution to the poor adherence to oral
therapies in schizophrenia. However, there have been few comparative studies on the effectiveness and tolerability
of first and second generation depot antipsychotics in a real clinical practice setting. The objectives of the present
study were to compare safety and outcomes in patients with schizophrenia initiated on risperidone long-acting
injection (RLAI) or first generation antipsychotic injections (FGAI) at a Mental Health Centre in British Columbia.
Methods: Data were collected by retrospective chart review of all active patients starting depot therapy who
were ≥ 18 years of age, had received at least 3 injections of depot antipsychotic and had no prior clozapine
treatment. Kaplan Meier survival curves were used to estimate probability of treatment discontinuation and
hospitalization.
Results: A total of 70 RLAI and 102 FGAI patient charts were reviewed. At baseline patients in both groups had
similar ages (39.7 and 42.7 years for RLAI and FGAI patients (p = 0.09), respectively) but FGAI patients had a longer
time since diagnosis (13.6 vs. 9.85 years (p = 0.003)). Treatment retention at 18 months was 77% for RLAI and 86%
for FGAI patients (p = 0.22) and 82% and 88% of patients, respectively (p = 0.28), had not been hospitalized.
However, RLAI analyses were compromised by lack of long-term patient data. Concomitant medication utilization
was similar in both groups except for anticholinergics which were used less frequently in RLAI patients (5.7% vs.
35.3%, p < 0.001). Adverse event frequency was also similar except for extrapyramidal symptoms (EPS) which were
more common in FGAI patients (52.9% vs. 17.0% for RLAI (p < 0.001)).
Conclusions: There was no apparent difference in treatment discontinuation or hospitalization between RLAI and
FGAI treated patients, although analysis was compromised by low patient numbers. However, decreased EPS with
RLAI may offer a significant clinical benefit to patients with schizophrenia.
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Schizophrenia is a chronic mental illness with a range of
symptoms which can lead to severe impairments in per-
sonal, social and occupational functioning [1]. The life-
time prevalence of schizophrenia is estimated at 0.55%
[2] which correlates to approximately 185,000 Canadians
with the disease. The disorder usually presents in early
adulthood and as many as 50-70% of patients will suffer
chronic relapses which lead to increased rates of
hospitalization and extended morbidity and mortality
[2,3]. The resulting economic cost is substantial, primar-
ily resulting from the extensive hospitalization of pa-
tients during relapse (approximately 50% of the cost),
while medication contributes approximately 6% of the
overall cost [4].
One of the contributing factors to relapse in schizo-
phrenia is poor or partial adherence to medication [5,6].
Although adherence in schizophrenia is a complex
phenomenon, route of administration (oral vs. depot),
treatment related side-effects and the effectiveness of
medication are key factors in defining levels of long-
term adherence [5,7,8]. Depot antipsychotics are often
initiated in patients who have shown evidence of poor
adherence or tolerability to oral medications [5]. How-
ever, although depot formulations of first generation or
typical antipsychotics may have a positive impact on ad-
herence, like their oral counterparts they have minimal
impact on negative symptoms of schizophrenia and cog-
nition and are associated with an increased risk of extra-
pyramidal symptoms (EPS) and tardive dyskinesia (TD)
[9,10]. These limitations reduce the capacity of both oral
and depot formulations of typical antipsychotics to pro-
vide effective control of schizophrenia [10].
Second generation or atypical antipsychotics are effect-
ive in the control of both positive and negative symp-
toms of schizophrenia and generally have a lower
incidence of EPS and TD and in some patients can pro-
vide clinical advantages over typical agents [9,11-13].
Risperidone long-acting injection (RLAI) was the first
atypical antipsychotic available in a depot formulation
and the efficacy and tolerability of this agent have been
demonstrated in clinical trials [14,15]. However, there is
a lack of information on the comparative effectiveness
and tolerability of typical and atypical depot formula-
tions of antipsychotics when used in a real world clinical
practice setting. In the present study, retrospective chart
review was used to assess the impact of RLAI and first
generation antipsychotic depot injections (FGAI) on pa-
tient outcomes at a Mental Health Centre in Canada.
Methods
A retrospective chart review was conducted from De-
cember 2008 to March 2009 on all active patients at the
Victoria Mental Health Centre, Partnership MedicationClinic (PMC), Victoria, British Columbia. The PMC is a
primary location for the administration of depot anti-
psychotic medications to outpatients. The primary out-
comes of this retrospective chart review were time to
treatment discontinuation and time to hospitalization
for patients on RLAI versus FGAI. Secondary outcomes
included assessment of adverse side effects of therapy,
including EPS and TD, duration of hospitalization and
use of concomitant medications.
The inclusion criteria were patients starting depot
therapy who were ≥ 18 years of age, having a DSM IV
diagnosis of schizophrenia, schizophreniform disorder,
or schizoaffective disorder, who had at least 3 injections
of a depot antipsychotic. Exclusion criteria included evi-
dence of a prior clozapine trial, documentation of active
alcohol or substance abuse, or current pregnancy/lacta-
tion. Charts were examined based on a complete list of
active patients at the PMC. The goal was to select all pa-
tients on RLAI and match them with an equal number
of patients on an FGAI. However, because of the rela-
tively small number of patients available, all patients at
the PMC meeting the inclusion criteria were included.
Charts were examined for the primary and secondary
outcomes for the first 18 months of exposure to FGAI
and/or RLAI.
Data collected included current antipsychotic medica-
tion and dose, concomitant psychiatric medications, pa-
tient age, gender, weight, time since diagnosis and
comorbidities. For patients who had exposure to both
RLAI and FGAI throughout their treatment history, in-
formation was recorded for each depot type, such that
patients could be included in both groups. Among pa-
tients who were exposed to multiple FGAIs, only the
first medication encounter was recorded. During the ex-
posure time to antipsychotic, the most recent Abnormal
Involuntary Movement Scale (AIMS) [16] and Simpson
Angus Scale (SAS) [17] scores were recorded, if available
from the chart. Cases of TD were identified if the score
on the AIMS met the Schooler Kane criteria (moderate
dyskinetic movement in one body area or mild dyski-
netic movement in two body areas) [18] or the patient
was reported to have TD. Patients were considered to
have EPS if they were using an anticholinergic medica-
tion or met the definition for EPS (mean global score of
0.3 or more on the SAS, or a raw score of three) [17].
Time to treatment discontinuation was assessed over the
entire period a patient had exposure to antipsychotic, re-
gardless of a hospitalization. If after hospitalization the
patient remained on the same depot antipsychotic, they
were considered survivors for the discontinuation group,
as depot therapy with the same agent continued. Pa-
tients who discontinued depot antipsychotic by choice
and then relapsed or were hospitalized after a period of
time were counted as a treatment discontinuation. All






Age (Years) 39.7 42.7 0.09
Gender (n (%) male) 45 (64.3) 63 (61.8) 0.74
Weight (Kg) 90.61† 89.88† 0.97
Time since diagnosis (Years) 9.85 13.6 0.003
*Abbreviations are; RLAI Risperidone long-acting injection, FGAI First
generation antipsychotic injection.
†Weight based on data on 41 and 52 patients for RLAI and FGAI, respectively.
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Database.
Kaplan Meier survival curves were used to estimate the
probability of treatment discontinuation and hospitalization
at 18 months. In addition, Cox proportional hazard
modelling was conducted to identify patient baseline
characteristics that were significant predictors of treatment
discontinuation or hospitalization. Comparisons between
treatment groups for categorical variables were analyzed by
the Pearson chi-square or Fisher’s exact method. For con-
tinuous variables with a parametric distribution, the stu-
dent’s t-test was used; for nonparametric variables, the
Kolmogorov-Smirnov (KS) test was used. P values below
0.05 were considered statistically significant; however, due to
the preliminary nature of this study, trends in the data were
also considered. Information was analyzed using SPSS Stat-
istical Software (version 17.0) and all statistical tests were
two-sided. Power was not calculated a priori as this was a
hypothesis generating preliminary study.
Ethics approval for the study was granted by the
Health Research Ethics Board of the Vancouver Island
Health Authority. Informed consent was not required
for this retrospective chart review.
Results
As shown in Figure 1, 222 patient charts were eligible
for review but 81 were excluded because they did not
meet study inclusion criteria. Of the remaining patients
(n = 141), 70 received RLAI and 102 FGAI while 31 pa-
tients were included in both treatment groups. At base-
line, patients in both treatment groups had similar
characteristics except for time since diagnosis where the
FGAI patients had a significantly longer duration of
diagnosis (13.6 years vs. 9.85 years for the RLAI group,
p = 0.003) (Table 1). Duration of follow-up was 15.9 ±
4.6 months for FGAI and 11.2 ± 5.6 months for RLAI.222 patients assessed for eligibili
141 patients included in review
31 patients included in both groups




Figure 1 Summary of chart review process. Mean dose per injection for
administration was as per the respective Product Monographs.The most common FGAI utilized was flupenthixol
decanoate (63 of FGAI patients (61.8%) at a mean dose
of 37 mg) while only 9 patients (8.8%) received haloperi-
dol decanoate at a mean dose of 79 mg, the mean RLAI
dose was 32 mg (Figure 1). See Table 2 for doses of
depot, oral and total antipsychotics in CPZ equivalents.
The Kaplan Meier survival curves for treatment dis-
continuation were similar for both groups with 77% of
RLAI and 86% of FGAI patients continuing treatment at
18 months (p = 0.22) (Figure 2). The mean survival time
for RLAI and FGAI was 16.0 (95% confidence interval
(CI), 14.9 to 17.1) and 16.7 (95% CI, 15.9 to 17.4)
months, respectively, based on the Kaplan Meier ana-
lysis. However, few RLAI patients had long-term drug
exposure; at 18-months only 19 patients were at risk in
the Kaplan Meier analysis vs. 76 for FGAI (Figure 2).
Further information on those who discontinued therapy
is provided in Table 3 and indicates no significant differ-
ences in proportion discontinued, the time to discon-
tinuation or in the major reasons for discontinuation
between the FGAI and RLAI treatment groups. Al-
though there were differences in the reasons for discon-
tinuation between groups relating to patient choice





63 flupenthixol decanoate (37 mg) 
16 zuclopenthixol decanoate (125 mg)
13 fluphenazine dacanoate (34 mg)
9 haloperidol decanoate (79 mg)
1 pipotiazine palmitate (50 mg)
each depot antipsychotic is shown in parenthesis; frequency of
Table 2 Does of antipsychotics for RLAI* and FGAI in CPZ
equivalents [19]
RLAI
Mean ± SD (mg)
FGAI
Mean ± SD (mg)
Depot Antipsychotics 386 ± 113 535 ± 368
Flupenthixol decanoate 550 ± 368
Zuclopenthixol decanoate 376 ± 193
Fluphenazine decanoate 824 ± 572
Haloperidol decanoate 316 ± 120
Pipotiazine palmitate 300 ± 0
Risperidone microspheres 386 ± 113
Oral antipsychotics 316 ± 220 370 ± 335
Depot + oral antipsychotics 505 ± 283 716 ± 596
* Abbreviations are: RLAI Risperidone long-acting injection, FGAI First
generation antipsychotic injection, CPZ chlorpromazine.
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tical significance.
Kaplan Meier analysis of time to hospitalization was
similar for both groups with 82% and 88% of patients in
the RLAI and FGAI groups, respectively, without a re-
lapse requiring hospitalization over the 18 month assess-
ment period (p = 0.28) (Figure 3). The mean survivalFigure 2 Kaplan Meier survival curve for time to treatment discontinu
injection) and FGAI (first generation antipsychotic injection) treated patienttime for hospitalization was 15.8 (95% CI, 14.5 to 17.0)
and 16.6 (95% CI, 15.8 to 17.4) months for RLAI
and FGAI patients, respectively. For those patients who
were hospitalized there were no significant differences in
time to first hospitalization or in mean duration
of hospitalization between RLAI and FGAI treatment
(Table 3). In both treatment groups the reason for
hospitalization was treatment failure. Cox proportional
hazards models indicated that no assessed baseline char-
acteristic (age, gender, time since diagnosis, patient
weight or treatment with RLAI vs. FGAI) was a signifi-
cant predictor of either treatment discontinuation or
hospitalization (results not shown).
During treatment with both depot formulations there was
extensive additional use of oral antipsychotics and psychi-
atric medications (Table 3). In the FGAI group, there was
greater utilization of additional oral antipsychotics (41.1% of
FGAI patients vs. 30% of RLAI patients), antidepressants
(25.5% vs. 14.3%) and anticholinergics (35.3% vs. 5.7%), but
only the latter was statistically significant (p < 0.001) with a
6.2-fold increase in anticholinergic use in FGAI patients.
The most commonly used adjunct oral antipsychotics
were quetiapine and olanzapine while procyclidine and
benztropine were the most common anticholinergics.ation. Survival curves are shown for RLAI (risperidone long-acting
s. Abbreviations are; RR, Risk Ratio; SD, standard deviation.
Table 3 Medication discontinuation, hospitalization patterns and concomitant medication utilization in RLAI* and FGAI
treatment groups
Outcome RLAI (n = 70) FGAI (n = 102) P value
Discontinuation
Proportion of patients discontinued (n (%)) 11 (15.7) 13 (12.7) 0.30
Mean time to discontinuation (Months ± SD) 7.2 ± 5.4 7.9 ± 4.8 0.99
Reason for discontinuation (n (%))
Patient choice 7 (63.6) 5 (38.5) 0.22
Intolerability 2 (18.2) 4 (30.8) 0.65
Treatment failure 2 (18.2) 0 (0) 0.20
Unknown 0 (0) 4 (30.8) 0.49
Hospitalization
Proportion of patients hospitalized (n (%)) 10 (14.3) 13 (12.7) 0.09
Mean time to hospitalization (Months ± SD) 5.4 ± 2.8 5.8 ± 5.1 0.80
Mean duration of hospitalization (Days ± SD) 35 ± 24 29 ± 17 0.49
Reason for hospitalization (n (%))
Treatment failure 10 (100) 13 (100) 1.00
Concomitant medications (n (%))
Additional antipsychotic 21 (30) 42 (41.1) 0.14
Anticholinergic 4 (5.7) 36 (35.3) <0.001
Mood stabilizer 13 (18.6) 11 (10.8) 0.15
Antidepressant 10 (14.3) 26 (25.5) 0.08
Benzodiazepine 7 (10.0) 9 (8.8) 0.79
*Abbreviations are; RLAI Risperidone long-acting injection, FGAI First generation antipsychotic injection, SD standard deviation.
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impact on the outcomes assessed. A sub-group analysis of
the 70% and 59% of RLAI and FGAI treatment groups, res-
pectively, who were receiving mono depot therapy (i.e.,
no additional oral antipsychotics) produced similar re-
sults for time to discontinuation and hospitalization to
those already described for the overall analyses (results
not shown).
As shown in Table 4, chart review indicated that simi-
lar proportions of both RLAI and FGAI patients had
AIMS and SAS assessments. Both mean AIMS and SAS
scores were higher for the FGAI treatment group, but
the differences were not statistically significant. Never-
theless, the SAS assessment indicated a 3.1-fold increase
(p < 0.001) in the incidence of EPS in the FGAI treated
group (52.9% vs. 17% of RLAI patients). Also, more pa-
tients in the FGAI group had TD (4.9% vs. 1.4% in RLAI
patients) but this difference was not statistically signifi-
cant (p = 0.40). Results were similar for patients in both
treatment groups receiving RLAI or FGAI monotherapy
without additional oral antipsychotics (results not
shown).
Reports of side effects of therapy recorded in patient
charts confirmed a higher incidence of movement disor-
ders in FGAI treated patients with 17.6% (vs. 14.3% forRLAI) and 23.5% (vs. 0% for RLAI) of patients with EPS
and tremor, respectively (Table 4). There were no major
differences in additional reported side effects between
treatment groups, although only 10% and 16.7% of RLAI
and FGAI patients, respectively, had such events
recorded in their charts.
Discussion
The aim of this study was to assess the impact of typical
and atypical depot antipsychotics on schizophrenia pa-
tient outcomes in a real world clinical practice setting
over an 18 month period. Retrospective chart review
showed high levels of continuation on depot therapy
with both FGAI and RLAI (86% and 77%, respectively,
p = 0.22) and relatively low rates of hospitalization
(12.7% and 14.3%, respectively, p = 0.09) with no signifi-
cant differences between the two formulations. However,
with RLAI there was a significantly lower incidence of
EPS (17% vs. 52.9%, p < 0.001) and evidence suggesting
reduced rates of TD and a lower utilization of oral anti-
psychotics, although these differences were not statisti-
cally significant.
Few studies have compared treatment retention and
hospitalization with FGAIs and RLAI in similar patient
populations in this type of clinical setting. However,
Figure 3 Kaplan Meier survival curve for time to hospitalization. Survival curves are shown for RLAI (risperidone long-acting injection) and
FGAI (first generation antipsychotic injection) treated patients. Abbreviations are; RR, Risk Ratio; SD, standard deviation.
Table 4 Abnormal movement assessments and side
effects of RLAI* and FGAI therapy
Treatment outcome RLAI FGAI P value
Abnormal movement
AIMS score completed (n (%)) 36 (51.4) 61 (59.8) 0.28
Mean AIMS score 1.83 3.25 0.25
Proportion of patients with TD (n (%)) 1 (1.4) 5 (4.9) 0.40
SAS score completed 33 (47.1) 54 (52.9) 0.45
Mean SAS score 2.82 4.85 0.28
Proportion of patients with EPS 12 (17.0) 54 (52.9) <0.001
Side effects of therapy (n (%))
Patients reporting side effects 7 (10.0) 17 (16.7) 0.21
EPS 1 (14.3) 3 (17.6)
Akathesia 1 (14.3) 2 (11.8)
Weight gain 2 (28.6) 2 (11.8)
Tremor 0 (0) 4 (23.5)
Galactorrhea 1 (14.3) 0 (0)
Other† 2 (28.6) 6 (35.5)
* Abbreviations are: RLAI Risperidone long-acting injection, FGAI First
generation antipsychotic injection, AIMS Abnormal Involuntary Movement
Scale, TD tardive dyskinesia, SAS Simpson Angus Scale, EPS
extrapyramidal symptoms.
†Other includes injection site pain, dizziness, fatigue, TD (FGAI) and mental
impairment (RLAI).
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retention rates; ranging from 49.8% over 36 months for
depot typical [20] and up to 85% for RLAI [21] over
24 months, although estimation of such rates in schizo-
phrenia are prone to differences in clinical practice pat-
terns and disease severity in treated patients [21]. In
addition, numerous studies have demonstrated that a
switch from oral antipsychotics to typical or atypical
depot formulations can lead to decreases in patient
hospitalization rates [21,22]. However, using a similar
retrospective chart audit methodology, Virit et al. [23]
assessed outcomes in schizophrenia patients in Turkey
who were switched from oral antipsychotics to FGAIs
(n = 46) or RLAI (n = 22). After mean treatment periods
of 20.4 and 15.2 months for FGAIs and RLAI (p = 0.02),
respectively, 90.9% of the latter patients were still on
therapy compared to 58.7% for FGAI (p = 0.02). This
suggested improved retention with RLAI, although
results may have been compromised by the lack of long-
term treatment data for RLAI because of its relatively re-
cent availability compared to FGAIs [23]. A similar
problem occurred in the present study where fewer
RLAI patients had long-term exposure to therapy com-
pared to FGAIs; only 17% of RLAI patients had exposure
beyond 18-months compared to 72% of FGAI patients
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spectively. As a result the current analysis was restricted
to a comparison over 18-months so that groups could
be compared on similar terms. The limited number of
patients with long-term RLAI data may have impacted
the validity of treatment retention and hospitalization
estimates in this population. Virit et al. [23] suggest that
treatment retention on RLAI in their study may be
higher than with FGAIs because of the significantly
lower incidence of adverse events (p = 0.02) with the
former antipsychotic.
In contrast, using a different methodology, Olfson
et al. [24] found no difference in treatment retention
rates between FGAIs and RLAI. By analysis of an admin-
istrative Medicaid database in the United States the au-
thors reported that 6 months after treatment initiation,
only 9.7%, 5.4% and 2.6% of patients were continuing
on haloperidol decanoate, fluphenazine decanoate and
RLAI, respectively, rates much lower than those
reported here. However, apart from the recognised limi-
tations of analyzing administrative databases [24],
the patients in this study also had high levels of
polypharmacy (≥ 70% to 93% of patients also received
oral antipsychotics during depot therapy), suggesting ex-
tensive psychiatric comorbidity which may have had a
negative impact on treatment retention [24].
In the present study 30% and 41.1% of RLAI and FGAI
patients, respectively, were using additional oral antipsy-
chotics. In clinical practice, antipsychotic polypharmacy
has been reported to range from 13% to 60% and can
have a significant impact on schizophrenia patient
outcomes [25,26]. However, in the present study
polypharmacy did not appear to impact the observed
outcomes. When the analyses were repeated on patients
receiving RLAI or FGAI monotherapy, all outcomes, in-
cluding incidence of movement disorders, were un-
changed suggesting that oral antipsychotics played no
role in defining treatment retention, hospitalization or
adverse events. In fact, the majority of additional anti-
psychotic prescriptions were for quetiapine dosed at
bedtime, indicating likely use as a sleep aid.
Both the RLAI and FGAI patient groups had simi-
lar characteristics at baseline, although time since
diagnosis was significantly longer in the latter group
(3.75 years longer). Therefore, it is possible that the
FGAI group were at a more stable course in their
disease and hence less prone to relapses, compared
to the RLAI group, who with a more recent diagno-
sis may have had more unstable disease. Similarly,
although not statistically significant, the RLAI group
was on average three years younger, again suggesting
a possible difference in disease course between the
two groups. These differences may have contributed
to the observed RLAI and FGAI outcomes.The present study presents clear evidence that
treatment with RLAI in an outpatient setting leads to
significantly lower rates of EPS and a trend towards a
lower rate of TD, compared to conventional depot
antipsychotics. This confirms previous studies which
have shown significant reductions in EPS and move-
ment disorders following a switch from FGAIs to
RLAI [27,28]. Although not assessed in the present
study, switching from a typical depot to RLAI has
also been shown to result in significant improvement
in Positive and Negative Syndrome Scale (PANSS)
scores suggesting a broad impact of RLAI on symp-
tom control in schizophrenia [27,28]. In the present
study, incidence of movement disorders was based
mainly on AIMS and SAS assessments recorded in
patient charts. However, only 56% and 50% of pa-
tients had AIMS and SAS evaluations, respectively,
despite Canadian Psychiatric Association guidelines
which recommend assessment every 6 months [29].
This suggests that these recommendations are not
universally applied in clinical practice. Symptoms of
EPS have a large impact on patient functioning and
can also affect adherence to antipsychotic medication,
hence the recommendation for frequent assessment
[29-31]. In the present study, the observation that
RLAI significantly decreases the incidence of EPS
compared to FGAIs, while providing high levels of
symptom control, may have significant implications
for long-term patient care with depot antipsychotics.
There are a number of limitations associated with
this study. Firstly, data were only collected from pa-
tients at the PMC currently receiving depot injec-
tions. As a result, patients who tried depots and
relapsed, or discontinued treatment earlier, were not
captured so the event rates found may not be a true
reflection of events in the overall schizophrenia popu-
lation. Secondly, retrospective chart review relies on a
consistent and comprehensive clinical record, which
may not always be the case, so clinical details may be
missing for some patients. In addition, there may also
have been misinterpretation of available data in the
charts by reviewers or a lack of clarification of miss-
ing data. Thirdly, a power calculation was not com-
pleted a priori because the number of charts available
was limited and the purpose of the review was ex-
ploratory. Finally, as discussed above, the small num-
ber of patients receiving RLAI beyond 18 months
may have compromised the validity of estimates of
treatment retention and hospitalization rates for this
patient population. Nevertheless, despite these limita-
tions, the study provides an assessment of usual care
outcomes for schizophrenia patients receiving depot
antipsychotic medications in a single Mental Health
Centre in Canada.
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There were no significant differences between treat-
ment retention and hospitalization rates in patients re-
ceiving RLAI or FGAI, although estimation of long-
term rates for the former were based on small numbers
of patients. However, RLAI treatment was associated
with a significantly lower incidence of EPS, a trend to-
wards a lower incidence of TD, and reduced utilization
of oral antipsychotics. The results emphasize the need
for a larger study comparing RLAI and FGAI treatment
in schizophrenia, one powered to detect clinically rele-
vant changes in patient outcomes.
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